Viking Therapeutics to Join Piper Sandler’s 37th Annual Healthcare Conference

Viking Therapeutics to Join Piper Sandler’s 37th Annual Healthcare Conference

By, Admin 26 November 2025

Viking Therapeutics is stepping into the spotlight this December. The metabolic-drug developer will share updates, answer investor questions, and highlight the progress of its leading programs.

Quick Highlights

  • Event: Piper Sandler 37th Annual Healthcare Conference
  • Dates: December 2–4, 2025
  • Fireside Chat: December 2, 2025, from 12:30 to 12:55 p.m. ET
  • Location: New York City
  • Format: Fireside chat + investor meetings

Why This Matters?

Viking is running some of the most closely watched trials in metabolic and endocrine disorders. The conference gives investors a front-row seat to the company’s latest data and direction.

Inside Viking Therapeutics: What the Company Is Building

Viking focuses on first-in-class and best-in-class therapies for tough metabolic diseases. Their programs target obesity, NASH, NAFLD, lipid disorders, and rare metabolic conditions.

VK2735: Dual GLP-1/GIP Agonist

VK2735 is Viking’s flagship program.

  • It activates GLP-1 and GIP receptors, two powerful metabolic pathways.
  • Phase 1 and Phase 2 data show strong tolerability and promising metabolic benefits.
  • Viking is running two formats: subcutaneous injections and an oral formulation now in Phase 2.

This program positions Viking inside the fastest-moving category in metabolic drug development.

VK2809: Selective Thyroid Hormone Receptor-Beta Agonist

VK2809 aims to solve lipid and liver-fat disorders with precision.

  • It succeeded in a Phase 2b trial for biopsy-confirmed NASH and fibrosis.
  • A Phase 2a NAFLD study showed meaningful drops in LDL-C and liver fat versus placebo.
  • The drug is orally available, which adds convenience and adherence advantages.

DACRAs: The New Obesity Frontier

Viking is also working on dual amylin and calcitonin receptor agonists (DACRAs).
These agents may shape the next generation of obesity therapies by targeting appetite, satiety, and energy balance through multiple hormonal pathways.

VK0214: Rare Disease Focus

VK0214 targets X-linked adrenoleukodystrophy (X-ALD).

  • It modulates the thyroid hormone receptor-beta pathway.
  • Phase 1b results showed strong tolerability and significant reductions in VLCFAs.
  • Early data signal potential disease modification for the AMN form of X-ALD.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!